IJImran Karim Janmohamed

Imran Karim Janmohamed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Imran Karim Janmohamed has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study

    by Imran Karim Janmohamed, Saleh Sahbi, Arsam Mahmood, Haasher Monib, Hamza Nawaz, Shabeeba Hannan, Anibe Ata, Luke Membrey

    Purpose: The increased injection volume of aflibercept 8 mg (0.07 ml versus 0.05 ml) raises theoretical concerns regarding intraocular pressure (IOP) effects. This study evaluated acute IOP dynamics following aflibercept 8 mg compared to aflibercept 2 mg and identified predictive factors for pressure elevation. Methods: 140 eyes of 127 patients receiving aflibercept 8 mg (70 eyes) or 2 mg (70 eyes) between January-December 2025 were included. IOP was measured at baseline (T0), immediately post-injection (T1), and 30 min post-injection (T2). Linear mixed-effects models assessed the effects of time, treatment group, and time-by-treatment interactions. Multivariable mixed-effects logistic regression was used to identify predictors of IOP >21mmHg and IOP elevation >5mmHg at T2. Results: Both formulations produced significant IOP elevations from baseline at T1 and T2 ( p < 0.001 within each group). Mean IOP increased from 14.0 mmHg to 39.3 mmHg (aflibercept 2 mg) and 14.5 mmHg to 39.3 mmHg (aflibercept 8 mg) immediately post-injection, with near-complete resolution by 30 min (16.9 vs 17.7 mmHg). No significant between-group differences were identified at any timepoint. Pre-existing glaucoma/OHT was the only consistent independent predictor of both IOP >21 mmHg (OR 3.00–3.31, p = 0.024–0.038) and IOP elevation >5 mmHg from baseline (OR 10.45–11.75, p < 0.001) at T2; aflibercept formulation was not associated with either outcome. No injection required paracentesis. Conclusion: Aflibercept 8 mg demonstrates comparable IOP dynamics to aflibercept 2 mg. Glaucoma/OHT represents the strongest predictor of early pressure elevation, warranting enhanced monitoring.

  • Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration

    by Imran Karim Janmohamed, Havena Harahn, Barnaby Carr, Saleh Sahbi, Hasan Ahmed, Abdelrahman Farahat, Shabeeba Hannan, Luke Membrey

    Real-world evidence of aflibercept 8 mg in treatment-experienced patients remains limited. This study evaluated early outcomes of switching treatment-refractory patients with neovascular age-related macular degeneration (nAMD) to aflibercept 8 mg. This retrospective cohort study analysed previously-treated patients who switched to aflibercept 8 mg between January and June 2025. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, macular fluid status and treatment intervals were evaluated at baseline, 3 months, 6 months and final visit. 58 patients (66 eyes) were included. Patients received a mean 24.98 ± 18.04 anti-VEGF injections per eye over 49.41 ± 35.74 months pre-switch. Mean 5.15 ± 1.51 aflibercept 8 mg injections were administered per eye over a mean follow-up period of 25.86 ± 8.34 weeks. Median treatment intervals increased significantly from baseline to final visit (4 to 6 weeks, p < 0.001). 23 eyes (34.8%) achieved ≥8-week intervals by final follow-up. Median BCVA remained stable (70 ETDRS letters, interquartile range [IQR] 62-76 baseline and final follow-up, p = 0.571), as did median CMT (230.5 μm (IQR 189.5-281.2) at baseline to 226.5 μm (IQR 195-257) at final follow-up, p = 0.494). Median PED height showed a significant reduction (175 μm (IQR 106-287) at baseline to 173 μm (IQR 105-251) at final follow-up, p = 0.045). Complete macular fluid resolution occurred in 23.9% of eyes with baseline fluid at the final visit. No serious ocular adverse events occurred in this cohort. Aflibercept 8 mg demonstrated modest interval extension with stable functional and anatomical outcomes in heavily pre-treated nAMD patients. Long-term studies are needed to establish durability.


  • 10-year analysis of microbiological profiles and in vitro antimicrobial susceptibility: the Kent microbial keratitis study

    by Imran Karim Janmohamed, Oluwadamilola Oguntoye, Lanxing Fu, Chloe Robson, Mohamed Elalfy, Sundas Maqsood

    Background To evaluate the incidence, microbiological profile, and in vitro antimicrobial susceptibility patterns of microbial keratitis (MK) in Kent over a 10-year period. Methods A retrospective analysis was conducted of all corneal scrape specimens processed between January 2015 and August 2024 at Maidstone and Tunbridge Wells NHS Trust and East Kent Hospitals University NHS Foundation Trust. Data extracted included patient demographics, isolates, and antimicrobial sensitivities. The study period was divided into two time periods (2015–2019 and 2020–2024) for trend analyses. Results The estimated mean incidence of MK was 2.2 per 100,000 population per year. Of 1029 scrapes, 384 were culture-positive (37.3%). Gram-negative organisms predominated (50.9%), followed by Gram-positive (37.8%), fungi (5.0%), and Acanthamoeba (6.3%). Polymicrobial infections accounted for 10.4% of cases. Pseudomonas spp (35.9%), Coagulase-negative Staphylococci (15.0%), and Staphylococcus aureus (9.8%) were most commonly isolated. Average susceptibility of Gram-positive organisms to chloramphenicol, fluoroquinolones, and gentamicin was 96.7%, 76.0% and 92.1%, respectively, and for Gram-negative organisms was 48.2%, 93.4%, and 99.3%, respectively. Concerning trends included a 16.9% reduction in fluoroquinolone susceptibility among Gram-positive isolates (p < 0.001), with moxifloxacin efficacy decreasing by 57.9% (p = 0.002). The prevalence of Acanthamoeba represents an unrecognised regional disease burden, exceeding other UK regions (1.1–4.8%). Discussion This study identified a marked decline in fluoroquinolone susceptibility among Gram-positive organisms and a significantly higher acanthamoeba prevalence compared to other UK regions and global reports. These findings highlight the importance of ongoing antimicrobial stewardship and support re-evaluation of empiric treatment protocols for MK in Kent.


  • Outcomes of descemet's membrane endothelial keratoplasty in patients under thirty years old

    by Shafi Balal, Imran Karim Janmohamed, Anna Song, Rohan Hussain, Sundas Maqsood, Vincenzo Maurino

    Background: Evidence for Descemet's membrane endothelial keratoplasty (DMEK) in patients under 30 years old remains limited, although understanding outcomes in this demographic is important given the requirement for decades of graft function and concerns about long-term DMEK survival. Methods: We conducted a retrospective case series at Moorfields Eye Hospital of consecutive patients under 30 years undergoing DMEK between 2015 and 2022. Primary outcome was change in best-corrected visual acuity (BCVA). Secondary outcomes included change in central corneal thickness (CCT), graft failure rates, and post-operative complications. Results: 18 eyes of 17 patients underwent DMEK surgery (mean age 22.7 ± 5.1) over a mean follow-up of 1072.1 ± 869.8 days. Mean BCVA improvement was 0.36 logMAR from pre-operative to final follow-up ( p > 0.05), though significant improvements occurred at 1-month and 12-month intervals ( p < 0.001 and p < 0.01, respectively). CCT improved significantly from baseline by 111.3 μm (95% CI, 64.3–158.2 μm, p < 0.0001). At final follow-up, 22.2% of eyes achieved BCVA ≤ 0.3 logMAR ( n = 4). No patient achieved BCVA ≤ 0.1 logMAR. Rebubbling was performed 9 times (50%) in 8 eyes and was similar between both SF6 and air ( p > 0.05). Post-operative complications occurred in 11.1% ( n = 2) with no rejection episodes, although secondary graft failure occurred in 22.2% ( n = 4), all within 12 months. Conclusions: DMEK effectively improves visual and anatomical outcomes in patients under 30, though with higher complication rates than older populations. The complex pathology and longer follow-up requirements in this demographic necessitate careful patient selection and realistic expectations. Larger prospective studies are needed to establish definitive guidelines for this population.

  • Complications and Management of Cosmetic Iris Implants

    by Shafi Balal, Omer Jamall, Imran Karim Janmohamed, Ibtesham Hossain, Rohan Hussain, Soyang Ella Kim, Gabriele Gallo Afflitto, Vincenzo Maurino


  • Faricimab-Associated Intraocular Inflammation With Features of Herpes Simplex Virus

    by Imran Karim Janmohamed, Muhammed Aizaz Us Salam, Omer Jamall, Mohamed Elgharably, Noha Ghoz, Aishwarya Amarnath, Korina Theodoraki, Goncalo Almeida


  • 1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration

    by Imran Karim Janmohamed, Adeel Mushtaq, Jamil Kabbani, Simeon Harrow, Aaruran Nadarajasundaram, Anibe Ata, Henrietta Monye, Zakariya Jarrar, Shabeeba Hannan, Luke Membrey

    Background and objectives Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients. Methods This single-centre retrospective cohort study included patients previously treated for nAMD who switched to faricimab between November 2022 and March 2024. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and treatment intervals were assessed at baseline, 6, and 12 months. Results One hundred eighty-four patients (215 eyes) were included. Patients had received a median of 18 (interquartile range [IQR] 10–28.5) anti-VEGF injections per eye over an average of 5.02 ± 11.82 years before switch. An average of 8.63 ± 2.2 faricimab injections were administered per eye over an average follow-up of 12.19 ± 2.70 months. Median BCVA decreased from 70 ETDRS letters (IQR 55–76) at baseline to 62 (IQR 47–76) at 12 months (p = 0.0038). Median CMT improved from 259.5 μm (IQR 223-299.75) at baseline to 232 μm (202.0–272.5) at 12 months (p < 0.0001). At the last follow-up, 40.2% of eyes were dry on OCT. The median dosing interval doubled from 4 weeks (IQR 4–4) to 8 weeks (IQR 6–10) with faricimab (p < 0.0001). 47.4% and 16.3% of eyes achieved treatment intervals of ≥8–12 weeks and ≥12 weeks, respectively. Three events of uveitis were noted following the loading phase. Conclusions This real-world study demonstrates that faricimab maintains vision and achieves significant anatomical improvements in treatment-experienced nAMD patients. The extended treatment intervals could significantly reduce the burden on patients and healthcare resources.


  • Open Access

    1-year Real-World Outcomes of Faricimab in Previously Treated Neovascular Age-Related Macular Degeneration

    by Imran Janmohamed, Adeel Mushtaq, Jamil Kabbani, Simeon Harrow, Aaruran Nadarajasundaram, Anibe Ata, Henrietta Monye, Zakariya Jarrar, Shabeeba Hannan, Luke Membrey

    Background and Objectives Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates one-year outcomes of faricimab in treatment-experienced nAMD patients. Methods This single-centre retrospective cohort study included patients previously treated for nAMD who switched to faricimab between November 2022 and March 2024. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and treatment intervals were assessed at baseline, 6, and 12 months. Results 184 patients (215 eyes) were included. Patients had received a median of 18 (interquartile range [IQR] 10-28.5) anti-VEGF injections per eye over an average of 5.02 ± 11.82 years before switch. An average of 8.63 ± 2.2 faricimab injections were administered per eye over an average follow-up of 12.19 ± 2.70 months. Median BCVA decreased from 70 ETDRS letters (IQR 55–76) at baseline to 62 (IQR 47–76) at 12 months (p = 0.0038). Median CMT improved from 259.5 µm (IQR 223-299.75) at baseline to 232 µm (202.0-272.5) at 12 months (p < 0.0001). At the last follow-up, 40.2% of eyes were dry on OCT. The median dosing interval doubled from 4 weeks (IQR 4–4) to 8 weeks (IQR 6–10) with faricimab (p < 0.0001). 47.4% and 16.3% of eyes achieved treatment intervals of ≥ 8–12 weeks and ≥ 12 weeks, respectively. Three events of uveitis were noted following the loading phase. Conclusions This real-world study demonstrates that faricimab maintains vision and achieves significant anatomical improvements in treatment-experienced nAMD patients. The extended treatment intervals could significantly reduce the burden on patients and healthcare resources.

  • Open Access

    Derivation and validation of a novel risk score to predict need for haemostatic intervention in acute upper gastrointestinal bleeding (London Haemostat Score)

    by Isobel Marks, Imran Karim Janmohamed, Sadek Malas, Athina Mavrou, Thomas Banister, Nisha Patel, Lakshmana Ayaru

    Background Acute upper gastrointestinal bleeding (AUGIB) is a common medical emergency, which takes up considerable healthcare resources. However, only approximately 20%–30% of bleeds require urgent haemostatic intervention. Current standard of care is for all patients admitted to hospital to undergo endoscopy within 24 hours for risk stratification, but this is difficult to achieve in practice, invasive and costly. Aim To develop a novel non-endoscopic risk stratification tool for AUGIB to predict the need for haemostatic intervention by endoscopic, radiological or surgical treatments. We compared this with the Glasgow-Blatchford Score (GBS). Design Model development was carried out using a derivation (n=466) and prospectively collected validation cohort (n=404) of patients who were admitted with AUGIB to three large hospitals in London, UK (2015–2020). Univariable and multivariable logistic regression analysis was used to identify variables that were associated with increased or decreased chances of requiring haemostatic intervention. This model was converted into a risk scoring system, the London Haemostat Score (LHS). Results The LHS was more accurate at predicting need for haemostatic intervention than the GBS, in the derivation cohort (area under the receiver operating curve (AUROC) 0.82; 95% CI 0.78 to 0.86 vs 0.72; 95% CI 0.67 to 0.77; pConclusions The LHS is accurate at predicting the need for haemostatic intervention in AUGIB and could be used to identify a proportion of low-risk patients who can undergo delayed or outpatient endoscopy. Validation in other geographical settings is required before routine clinical use.


  • Mitral valve paravalvular leaks: Comprehensive review of literature

    by Imran Karim Janmohamed, Vaibhav Mishra, Alexander Geragotellis, Mohamed Sherif, Amer Harky

    Background Mitral paravalvular leaks (mPVL) are a recognized complication for patients with mitral valve prostheses. Although clinically insignificant for many patients, it may pose life-threatening haemolysis and regurgitation-induced heart failure, and so clinicians should have a high index of suspicion in the presence of new symptoms. Aims This review discusses the pathogenesis, clinical features, diagnosis, imaging and treatment of mPVLs. Methods A comprehensive literature search was performed using PubMed, EMBASE, Cochrane database, Google Scholar and Ovid. Search terms used included “mitral valve paravalvular leak,” “transthoracic echocardiography,” “2D transoesophageal echocardiography,” “3D transoesophageal echocardiography,” “cardiac computed tomography,” (CT) “cardiac magnetic resonance imaging,” “intracardiac echocardiography,” “cinefluoroscopy,” “fluoroscopy,” and “percutaneous closure.” Results All patients with mPVLs should undergo regular full evaluation, including patient history, physical examination, laboratory work-up, imaging, and referral, if necessary. Echocardiography is fundamental to the diagnosis, and is augmented with cardiac magnetic resonance imaging, cardiac computerized tomography and fluoroscopy for further characterization and procedural planning amongst the structural heart team. Conclusion The prevalence of mPVL is expected to increase proportionally to the growing number of surgical and transcatheter valve replacements conducted in the ageing population. Multimodal imaging is instrumental in guiding diagnostic and therapeutic strategies when managing mPVLs. Advances in imaging and capabilities of transcather devices will prompt growing uptake of percutaneous treatment over conventional, higher-risk surgery for mPVL management.